Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.42 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.42 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.39 |
| ▸ | PTGFR | P43088 | 2/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.39 |
| ▸ | PTGIR | P43119 | 2/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050505 | 1.00 | CYP2C9 (0.45) | CYP2C9CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL1050357 | 0.92 | ENPP2 (0.44) | CYP2C9CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL4098769 | 0.92 | ENPP2 (0.44) | CYP2C9CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL1049936 | 0.92 | ENPP2 (0.42) | CYP2C9CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL4101180 | 0.92 | ENPP2 (0.42) | CYP2C9CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL1050561 | 0.91 | ENPP2 (0.42) | CYP2C9CYP1A2CYP2D6ENPP2SLC16A3 | |
| SCHEMBL1049961 | 0.91 | SLC16A3 (0.41) | CYP2C9ENPP2SLC16A3SLC16A1MCTS1 | |
| SCHEMBL1050565 | 0.91 | ENPP2 (0.42) | CYP2C9CYP1A2CYP2D6ENPP2SLC16A3 | |
| SCHEMBL1049962 | 0.91 | SLC16A3 (0.41) | CYP2C9ENPP2SLC16A3SLC16A1MCTS1 | |
| SCHEMBL1048828 | 0.90 | LMNA (0.41) | CYP2C9CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | claimed |
| US-8377958-B2 | Lonidamine analogues for fertility management | THE UNIVERSITY OF KANSAS (US) | 2013-02-19 | — | — | US | claimed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | claimed |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS | 2011-03-10 | — | — | US | claimed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | claimed |
| EP-2854865-B1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG LLC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10023864-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta | BERG LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-9533002-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β | BERG LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150353930-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG LLC | 2015-12-10 | — | — | US | disclosed |
| US-20140154266-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | BERG PHARMA LLC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS | 2011-03-10 | — | — | US | disclosed |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | UNIVERSITY OF KANSAS | 2011-03-10 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353930-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | HSP90AB1, HSP90AB2P, HSP90AA1 | CYP2C9 4450/4885CYP1A2 4117/4885CYP3A4 4580/4885 |
| US-10023864-B2 | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta | HSP90AB1, HSP90AB2P, HSP90AA1 | CYP2C9 4450/4885CYP1A2 4117/4885CYP3A4 4580/4885 |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | CYP2C9 784/4885CYP1A2 348/4885CYP3A4 1218/4885 |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, RAF1 | CYP2C9 3125/4885CYP1A2 4345/4885CYP3A4 3630/4885 |
| US-20140154266-A1 | METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90-BETA | HSP90AB1, HSP90AB2P, HSP90AA1 | CYP2C9 4297/4885CYP1A2 3639/4885CYP3A4 4274/4885 |
| US-20110060003-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | CYP2C9 784/4885CYP1A2 348/4885CYP3A4 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.